Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

McMaster University

$169,520.00

Engineering Starch-Based Nanoparticles and Nanoparticle Clusters for Improving Local Drug Delivery to Tumour Cores and the Brain

FY 2018-19

Summary
Delivering drugs using nanoparticles has been demonstrated in multiple cases to improve the*ability of drugs to get to their target sites, particularly in cases in which drugs must be*transported inside cells to be functional and/or drug must be transported from the blood*through hard-to-penetrate biological barriers (e.g. into the brain or through dense tissues such*as tumour masses). Starch nanoparticles (SNPs), developed by our partner EcoSynthetix,*have particular potential for drug delivery in this context given their capacity for direct loading*of drug during fabrication, their extremely small sizes, their gel-like properties (and thus*potential to deform under stress), and their biological inertness. However, there are two*inherent limitations to using SNPs for drug delivery: (1) drug release from SNPs is very fast*given their porous structures and (2) the small size of SNPs, while ideal for penetrating into*the brain or deep into tumours, also induces relatively fast clearance of SNPs from normal*circulation, restricting the capacity of SNPs to transport drugs to target sites. In this proposal,*we aim to address these challenges by (1) engineering the surface of SNPs to adjust drug*release rates to desired values and (2) developing methods of fabricating controlled clusters*of SNPs with good circulation properties that can be selectively degraded where drug release*is desired (either by specific chemistry at the target site or by external activation after a*specific time). We anticipate that such SNP-based materials will significantly improve the*delivery of drugs not only deep inside tumours and both into and within the brain (our two*proof-of-concept demonstrations) but also other diseases in which effective therapy is limited*by drug transport. Such capacity is anticipated to both improve health outcomes for*Canadians suffering from such diseases as well as provide a new, value-added market to*EcoSynthetix that will promote new job creation in Canada.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
508393-2017
Name nom
Hoare, Todd
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
169520
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2
Nb partie
3
Application title
Engineering Starch-Based Nanoparticles and Nanoparticle Clusters for Improving Local Drug Delivery to Tumour Cores and the Brain
Keyword
NSERC
Application summary
Delivering drugs using nanoparticles has been demonstrated in multiple cases to improve the*ability of drugs to get to their target sites, particularly in cases in which drugs must be*transported inside cells to be functional and/or drug must be transported from the blood*through hard-to-penetrate biological barriers (e.g. into the brain or through dense tissues such*as tumour masses). Starch nanoparticles (SNPs), developed by our partner EcoSynthetix,*have particular potential for drug delivery in this context given their capacity for direct loading*of drug during fabrication, their extremely small sizes, their gel-like properties (and thus*potential to deform under stress), and their biological inertness. However, there are two*inherent limitations to using SNPs for drug delivery: (1) drug release from SNPs is very fast*given their porous structures and (2) the small size of SNPs, while ideal for penetrating into*the brain or deep into tumours, also induces relatively fast clearance of SNPs from normal*circulation, restricting the capacity of SNPs to transport drugs to target sites. In this proposal,*we aim to address these challenges by (1) engineering the surface of SNPs to adjust drug*release rates to desired values and (2) developing methods of fabricating controlled clusters*of SNPs with good circulation properties that can be selectively degraded where drug release*is desired (either by specific chemistry at the target site or by external activation after a*specific time). We anticipate that such SNP-based materials will significantly improve the*delivery of drugs not only deep inside tumours and both into and within the brain (our two*proof-of-concept demonstrations) but also other diseases in which effective therapy is limited*by drug transport. Such capacity is anticipated to both improve health outcomes for*Canadians suffering from such diseases as well as provide a new, value-added market to*EcoSynthetix that will promote new job creation in Canada.